Covaxin Is 78% Effective Against Mild To Severe Covid-19 Infections: Bharat Biotech outlookindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outlookindia.com Daily Mail and Mail on Sunday newspapers.
Phase-3 Trials: Covaxin Demonstrates 100 Per Cent Efficacy Against Severe COVID-19, Overall Interim Clinical Efficacy 78 Per Cent
by Swarajya Staff - Apr 21, 2021 10:42 AM
Bharat Biotechâs COVAXIN
Bharat Biotech and the Indian Council of Medical Research (ICMR) on Wednesday (21 April) announced phase 3 interim analysis results of India s first indigenous COVID-19 vaccine, Covaxin.
In a statement, Hyderabad-based Bharat Biotech said that the second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease, said the company.
Bharat Biotech’s Covaxin has shown an overall efficacy of 78 per cent against Covid-19 and 100 per cent efficacy against a severe form of the disease, the vaccine maker said on Wednesday.
The vaccine has also shown 70 per cent efficacy against asymptomatic infections, suggesting that it prevents transmission. The second interim analysis of Covaxin’s Phase 3 clinical trials is based on accruing 87 symptomatic cases of the virus.
Trials are double-blinded and the investigator and volunteer do not know if they have received a placebo or a vaccine shot. After a certain statistical number of cases of the disease are reported in the sample, the data is un-blinded to see whether those in the vaccinated arm got the disease.
Covaxin shows 78% efficacy against mild, moderate severe Covid cases Bharat Biotech vaccine 70 per cent efficient in asymptomatic patients according to interim analysis results
Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown efficacy of 78 per cent against mild, moderate and severe cases of Covid-19, as per Phase III interim analysis results.
The vaccine maker noted that the second interim data of the Phase III study also showed that chances of hospitalisation due to the infectious disease were reduced by 100 per cent after taking the Covaxin jab.
“Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe Covid-19 disease,” Bharat Biotech said in a statement.
Notified new policy on rare diseases, approved budget of Rs 25 crore for treatment: Centre to HC
Notified new policy on rare diseases, approved budget of Rs 25 crore for treatment: Centre to HC
PTIApr 19, 2021, 20:51 IST
New Delhi, Apr 19 () The Centre on Monday told the Delhi High Court that it has notified the National Health Policy for Rare Diseases and transferred Rs four crore to AIIMS while approving a budget estimate of Rs 25 crore for the year 2021-22, all towards treatment of such ailments.
Apart from these, the Health Ministry said that it has also written to the All India Institute of Medical Sciences (AIIMS) to create a consortium of Centre of Excellences (envisaged for prevention and treatment of Rare Diseases).